Manuscript accepted on :
Published online on: 28-12-2013
3-HMG-CoA Reductase Inhibitors and Inflammation: Underlying Mechanisms and Role in Atherosclerosis
Ndubuisi N. Nwobodo
Department of Pharmacology and Therapeutics, Faculty of Clinical Medicine, Ebonyi State University, Abakaliki Nigeria.
DOI : http://dx.doi.org/10.13005/bbra/1181
ABSTRACT:
The 3-HMG-CoA reductase inhibitors, referred to as statins, are one of the most potent lipid lowering drugs. They significantly reduce incidence of cardiovascular mortality and morbidity. Data from clinical trials and experimental evidence suggest that the observed benefits can be attributed in part to their cholesterol-lowering independent effects. Statins lower the level of hs-CRP, an important inflammatory marker, thereby reducing the risk of stroke and cardiovascular events. The need for routine assay of hs-CRP is advocated in identifying patients at risk, that may benefit from statin therapy.
KEYWORDS: Atherosclerosis; C-reactive Protein(CRP); Cholesterol; Inflammation; Statins
Download this article as:
| Copy the following to cite this article: Nwobodo N. N. 3-HMG-CoA Reductase Inhibitors and Inflammation: Underlying Mechanisms and Role in Atherosclerosis. Biosci Biotechnol Res Asia 2013;10(2) |
| Copy the following to cite this URL: Nwobodo N. N. 3-HMG-CoA Reductase Inhibitors and Inflammation: Underlying Mechanisms and Role in Atherosclerosis. Biosci Biotechnol Res Asia 2013;10(2). Available from:https://www.biotech-asia.org/?p=10754 |
This work is licensed under a Creative Commons Attribution 4.0 International License.
